KYORIN Pharmaceutical Co Ltd: Segment Analysis

KYORIN Pharmaceutical Co Ltd (Kyorin), formerly Kyorin Holdings Inc, is a pharmaceutical company that offers prescription medicines, generic drugs, quasi-drugs, reagents, intermediates and other products. It also sells diagnostic products and industrial chemicals. Kyorin's business portfolio includes new drug discovery and development, new drug introduction, and new drug sales. The company is actively involved in infectious disease-related products, over-the-counter drugs, and generic drugs production.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company's R&D activities focus on developing products in the areas of respiratory, otolaryngology, urology, infectious disease, rare and intractable diseases. Its pipeline products include KRP-R120, a fusion protein drug in Phase III clinical trials indicated for the treatment of inflammatory diseases such as pulmonary sarcoidosis; KRP-114VP, currently in Phase I clinical trials being developed for the treatment of overactive bladder; and KRP-A218 being developed for the treatment of rhinovirus infection, currently in Phase I clinical trials. The Takaoka Pharmaceutical Technology Innovation Center is a key R&D unit of Kyorin. The center is responsible for maintaining and strengthening the company's in-house development capabilities for new generic products. It handles patent searches, planning strategies for development items, evaluations of pharmaceutical ingredients, formulation design, quality evaluation, clinical trials, and drug concentration measurements. The company operates R&D facilities in the US, Germany, Japan. It also operates WATARASE Research Center which is equipped with state-of-the-art equipment and instruments, connects individual research capabilities, encouraging ease of communication between researchers. KYORIN seeks to work in partnership with other pharmaceutical companies to enhance its pipeline products. The company’s R&D partners include Chem, JEIL Pharmaceuticals, Ferring International, Senju Pharmaceutical, Eisai, Bristol-Myers Squibb, MediciNova, Merck & Co, Allergan, and Kissei Pharmaceutical, among others. In FY2025, the company spent JPY10,514 million on its R&D activities, which as a percentage of revenue stood at 8.1% and grew 31.1% YoY.